To further investigate whether there may be differences in leukaemic cancer stem cell properties between P53/R26+/+ control and P53/R26-Zeb2tg/+ or P53/R26-Zeb2tg/tg tumours, we performed serial dilution tumour transplantation experiments in immunodeficient NOD/SCID mice. The gene discussed is TP53; the disease is cancer.